Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That other place, after putting my heart into helping others sucked the life out of me. Hopefully i'm getting back to what i love.
And thank you!
Close watch,$DPLO
Diplomat Pharmacy Inc ($DPLO)
$5.84 -0.03 (-0.51%) 02/25/19 [NYSE]
5.89 x 1 5.93 x 21
Post-market 5.90 +0.06 (+1.03%) 17:59 ET
https://www.barchart.com/stocks/quotes/DPLO
Solid Biosciences Inc.
(NASDAQ : $SLDB)
9.82 +0.86(9.60%)
SLDB After-Hours: 9.87 +0.91 (10.16%) as of 5:05PM
Alerted on Thursday, 02/14/19 03:25:43 PM @ $7.86
Read more at http://thestockmarketwatch.com/stock/?stock=SLDB#tsHBK40pEZH8hr6I.99
Its not over by a long shot. All we can do is play with caution!
Solid Biosciences Inc.
(NASDAQ : $SLDB)
8.645 +0.445(5.43%)
Read more at http://thestockmarketwatch.com/stock/?stock=SLDB#IakA3z1EB7salGj8.99
Thanks for the heads up, Welcome to D&Rip.
Just getting back to stocks. Been a while!
Hey salty How you been? Hope all is well!
Thanks bud, Hope all is well!
MTFB 2.69-0.12(-4.27%)
MTFB After-Hours: 2.75 -0.06 (-2.14%) as of 7:47
PM
Read more at http://thestockmarketwatch.com/stock/?stock=MTFB#uPSocDEvoODlEwZQ.99
MTFB PreMarket: $3.05 +0.24 (8.54%) as of 8:16
AM
Read more at http://thestockmarketwatch.com/stock/?stock=MTFB#lq33flS4fwC0jUic.99
Close watch, Solid Biosciences Inc.
(NASDAQ : SLDB)
$7.86 -0.47(-5.64%)
Read more at http://thestockmarketwatch.com/stock/?stock=SLDB#agrp4Dsxt5AO4wjP.99
Possible dip & rip Motif Bio Plc Sponsored ADR
(NASDAQ : MTFB)
$2.80 -7.2701(-72.19%)
Read more at http://thestockmarketwatch.com/stock/?stock=MTFB#9PrFKy5PSCpuwdUy.99
$BIOAQ up over 200% from low!
Please show some that supports yours? Go $BIOAQ
backing your opinion with documents is better
$GMGI moves on air, This is awesome!
Looks like someone may know something. Go $GMGI
The other thing that is undeniable, We are up over 100% from $BIOAQ's lows!
BioAmber, Inc.
(Other OTC/NBB : $BIOAQ)
0.021
+0.006265
( 42.52%)
Read more at http://thestockmarketwatch.com/stock/?stock=BIOAQ#Mf0tY4g4QFmHBiC1.99
Half a billy, Go $SBES
Merry Christmas guy's we will be back soon!
Merry Christmas to you and yours.
Soon it will be buying time again!
$BIOAQ has become a .01 a day, plus iron!
Don't look like it, BioAmber Inc. (BIOAQ)
0.061 ? 0.0115 (23.23%)
Volume: 8,177,494
Nice, Congratulation and take the time to enjoy it. God bless and take care.
I'm going camping and fishing right now, for 10 days.
Have fun guys!
Thanks buddy, Doing very well.
Been really busy. Put your picks on watch
Have fun and god bless!
Hey buddy how you been? I have been wicked busy on the cars.
Looks like going to be a very good year. Weird but good!
Provectus News
Provectus Biopharmaceuticals Expands Global Patent Portfolio for Active Pharmaceutical Ingredient Manufacture
Tuesday June 19, 2018
KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus today announced that the Indian Patent Office (IPO) has granted the Company's patent application for the synthetic process used to produce the active pharmaceutical ingredient (API) in PV-10, which is Provectus' lead investigational oncology drug. The Company's patent estate associated with API manufacturing provides intellectual property protection in a number of countries in Asia, Europe, and North America into the 2030s.
IPO patent 297453 is linked to U.S. patent (USP) 8,530,675, entitled "Process for the Synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenzofuran-1,9-xanthen]-3-one (Rose Bengal) and Related Xanthenes," which was awarded by the United States Patent and Trademark Office (USPTO) in 2013. The Company received related awards from, among others, the European Patent Office (EPO), the Japan Patent Office (JPO), and the State Intellectual Property Office (SIPO or the Chinese Patent Office) in 2015.
Continuations of Provectus' foundational manufacturing patent include USP 9,273,022 and USP 9,422,260, which were awarded by the USPTO in 2016.
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (Provectus or the Company) is a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers in adults and children.
The complete press release is available at https://www.provectusbio.com/news/press-releases/provectus-pr-20180619-1 on the Provectus website.
SOHM Releases Some Shareholder Updates in view of Some Rumors
06/04/2018 posted in Press Releases
Share
2
SOHM Releases Some Shareholder Update in view of some falsely made claims by some unhappy investors or groups.
Chino Hills, CA—June 4, 2018– SOHM, Inc. (PINKSHEETS: SHMN) a globally-known generic pharmaceutical manufacturer would like to clarify certain information and facts as following.
We have received some concerns from some concerned shareholders to clarify about some disgruntled investors are sharing some falsely made claims about company and its operation on various company boards like ihub etc. We would like to clarify some of them that;
(a) Company has not exercised any reverse splits in the last 10 years. Sohm, Inc did a reverse split when we took over management of the company from previous management team back in August 2008. After that Sohm, Inc has not exercises any reverse splits. Back in November 2017 we cancelled our only possible reverse split through a press release. Again, currently our management team is not considering any reverse split in the interest of every stakeholders including investors. It had confirmed also again few days back.
(b) They also claim that company revenues for Q1 is thru selling of company stocks, which is again made with some personal interest or grudges it seems. It is completely misguiding with vested interest. Company revenue is through its sell of products and services.
(c) Their claims are that company has issued approx. 545 million stocks in last 5 months, which is again false. After August 2015, company has not issued any stocks including to any of its directors or promoters except in April 2018 when company has honored it’s one of its old notes and stock issued were approx. 108 million.
(d) Company is working with its counsel to work with OTC to satisfy its compliance to move to Current and appropriate time when we come to know the progress, company would inform its shareholders with updates.
Hope this insight clarifies major concerns of the shareholders. At the same time, we strongly recommend and request every investors and shareholders to do their own due diligence before investment in the company. Instead of answering every shareholders who communicate us, we preferred to release our information through press release.
We are committed to do whatever possible and within our reach to do better operation and bring more and more transparency in company’s updates like we have been doing since taken over the management back in 2008.
Management is working towards company’s development and we have reiterated it several times.
Thank you, all shareholders!
About SOHM, Inc.
SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a global presence and marketing plan that assure continuous growth. SOHM manufacturing and marketing target the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing in India as well as strategic alliance with US manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and was introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To know more about SOHM, Inc., visit www.SOHM.com
Safe Harbor Statement:
This news release contains “forward-looking statements”, which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on for the most recent fiscal year, our quarterly reports uploaded from time-to-time on OTCMarkets.com.
For more information, please contact:
SOHM, Inc.
714-522-6700
https://www.sohm.com/2018/06/04/sohm-releases-some-shareholder-updates-in-view-of-some-rumors/
Provectus Biopharmaceuticals and Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) Announce PV-10 Abstract at American Society of Clinical Oncology (ASCO) Annual Meeting
Research undertaken at POETIC member institutions Alberta Children's Hospital (Canada) and Memorial Sloan Kettering Cancer Center identifies PV-10 activity, mechanisms of action, drug synergy, and in vivo activity
Preclinical data support advancing clinical development of PV-10 into early-stage clinical trial for refractory pediatric solid tumors
Thursday May 17, 2018
KNOXVILLE, TN & New York, NY, /GLOBE NEWSWIRE/ -- Provectus and POETIC today announced preclinical PV-10 data from pediatric cancer research that will be presented at the 2018 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, IL.
PV-10 induced cell death in pediatric solid tumor cell lines derived from relapsed pediatric neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma with a measurable therapeutic window compared to normal cells. Western blot analyses of cells treated with PV-10 indicated induction of apoptosis. Drug combination studies showed synergy with radiation and agents that target mitosis. Xenograft studies showed significant reduction of tumor burden in PV-10-treated mice compared to control animals, with a corresponding increase in overall survival.
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) ("Provectus" or the "Company") is a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for adult and pediatric solid tumor cancers. The Pediatric Oncology Experimental Therapeutics Investigators' Consortium ("POETIC") is a group of North American academic medical centers developing new pediatric cancer therapies.
Findings will be highlighted in a poster presentation on Saturday, June 2 from 8:00 to 11:30 a.m. CDT in Hall A as part of the Pediatric Solid Tumors topic during the Pediatric Oncology session. The POETIC poster title is "In vitro and xenograft anti-tumor activity, target modulation and drug synergy studies of PV-10 against refractory pediatric solid tumors," the poster board number is 230, and the abstract number is 10557.
This preclinical pediatric cancer research was led by Aru Narendran, MD, PhD and researchers at the POETIC Laboratory for Pre-Clinical and Drug Discovery Studies at the University of Calgary (Canada), together with Tanya Trippett, MD, Director of POETIC and researchers at Memorial Sloan Kettering Cancer Center.
Dr. Trippett said, "POETIC's mission is to promote the early clinical development of promising therapies for the treatment of children, adolescents, and young adults with cancer. We hope our collaboration with Provectus on PV-10 leads to an opportunity to improve cancer care for children around the world."
Ed Pershing, Chair of Provectus' Board of Directors, said, "We are thrilled to work alongside POETIC and its member institutions in Canada and the U.S. in an effort to jointly advance options for pediatric cancer patients around the globe."
The complete press release is available at https://www.provectusbio.com/news/press-releases/provectus-pr-20180517-1 on the Provectus website.
Battery metals supply crunch to slow near-term EVs growth — Moody's
http://www.mining.com/battery-metals-supply-crunch-slow-near-term-evs-growth-moodys/?utm_source=digest-en-mining-180501&utm_medium=email&utm_campaign=digest
Second Study of Expanded Access Patients Treated with PV-10 for In-Transit Melanoma Published in Journal of Surgical Oncology
Thursday April 19, 2018
KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers, today announced that the Journal of Surgical Oncology ("JSO") had published results from an investigator-led, single-center study of patients with in-transit melanoma who received intralesional PV-10 under expanded access. The JSO article detailed the experience of investigators at the Princess Alexandra Hospital in Brisbane, Australia treating 45 patients with almost exclusively Stage III disease from 2008 to 2015.
The current article may be accessed via the JSO's website at https://onlinelibrary.wiley.com/doi/10.1002/jso.24921.1
Patients and Key Results
Baseline characteristics: 60% men; median age of 76 years (range 51-90); 96% Stage IIIIB-C; median of 2 prior directed locoregional therapies
Median of 6 lesions treated with PV-10 (range 1-31); median of 2 treatments with PV-10 (range 1-4)
Per patient best overall response: 42% complete response, 44% partial response, and 7% stable disease
22% durable response rate (an objective response lasting more than 6 months from the time of first PV-10 treatment)
Median overall survival of 25 months from the first PV-10 treatment; 12-, 24-, 36-, and 48-month overall survival rates of 90%, 85%, 68% and 65%, respectively, from the time of first PV-10 treatment
At least one Grade 1 or 2 treatment-associated adverse event per patient; a total of three treatment-associated Grade 3 adverse events (treatment site ulceration, cellulitis, and photosensitivity reaction)
Dominic Rodrigues, Chairman of the Company's Board of Directors, said, "These data are consistent with prior analyses of patients treated with PV-10 in monotherapy settings as well as the clinical expectations underlying the design of our ongoing pivotal Phase 3 trial. This and other expanded access work, together with our historical and ongoing melanoma clinical trials, strongly support the continued relevance of PV-10 for the treatment of melanoma."
About PV-10
Provectus' lead investigational cancer drug product, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.
About In-Transit Melanoma
According to the current NCCN Guidelines for Patients®, Melanoma, Version 1.2016 2, Stage III in-transit melanoma is when cancer cells have spread into lymph vessels near the first tumor but not into nearby lymph nodes. Melanoma that has spread to a small area of skin near the first tumor is called satellite metastasis. Non-metastatic recurrence is melanoma that has come back after treatment but has not spread to distant parts of the body. According to the NCCN Guidelines for Melanoma, version 1.2018 3, under Treatment for Stage III In-transit Disease, " the tumor burden, time course of appearance, and duration of in-transit disease is variable. In some patients, in-transit lesions remain confined to a region of the body for many years. This may occur in isolation or in combination with other sites of metastatic disease. A major concern in patients in which in-transit disease occurs in isolation is the high probability of subsequent development of visceral metastasis."
About Our Phase 3 Trial of PV-10 as a Monotherapy for Stage III-VI M1a Melanoma
For patients with locally advanced cutaneous melanoma, Provectus is evaluating IL PV-10 versus chemotherapy (dacarbazine or temozolomide) or oncolytic viral therapy in an international, multi-center, pivotal Phase 3 trial (NCT02288897). In-transit, satellite and locally recurrent melanoma patients (Stage IIIB, IIIC or IV M1a) with at least one injectable lesion who are not candidates for treatment with either a checkpoint inhibitor or targeted therapy (with BRAF or combined BRAF/MEK inhibitors) are eligible. The trial's primary endpoint is progression-free survival (assessed via RECIST 1.1 every 12 weeks up to 18 months); complete response rate and overall survival are key secondary endpoints. More information about this Phase 3 trial is available via ClinicalTrials.gov:
https://www.clinicaltrials.gov/ct2/show/NCT02288897
About Provectus
Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017).
References:
1. The first study of expanded access patients treated with PV-10 for in-transit melanoma was authored by investigators at Peter MacCallum Cancer Centre in Melbourne, Australia: Lippey at al., Intralesional PV-10 for in-transit melanoma - a single-center experience. J Surg Oncol. 2016;114: 380–384. https://onlinelibrary.wiley.com/doi/10.1002/jso.24311. Accessed March 15, 2018.
2. National Comprehensive Cancer Network. Patients, Melanoma (Version 1.2016). https://www.nccn.org/patients/guidelines/mpm/files/assets/common/downloads/files/mpm.pdf. Accessed March 15, 2018.
3. National Comprehensive Cancer Network. Melanoma (Version 1.2018). https://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf (registration required). Accessed March 15, 2018.
The complete press release is available at https://www.provectusbio.com/news/press-releases/provectus-pr-20180419-1 on the Provectus website.
$PVCT, Provectus News
Provectus Biopharmaceuticals Expands Global Patent Portfolio for Cancer Combination Therapy
Thursday April 19, 2018
KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers, today announced that the Journal of Surgical Oncology ("JSO") had published results from an investigator-led, single-center study of patients with in-transit melanoma who received intralesional PV-10 under expanded access. The JSO article detailed the experience of investigators at the Princess Alexandra Hospital in Brisbane, Australia treating 45 patients with almost exclusively Stage III disease from 2008 to 2015.
The current article may be accessed via the JSO's website at https://onlinelibrary.wiley.com/doi/10.1002/jso.24921.1
Patients and Key Results
Baseline characteristics: 60% men; median age of 76 years (range 51-90); 96% Stage IIIIB-C; median of 2 prior directed locoregional therapies
Median of 6 lesions treated with PV-10 (range 1-31); median of 2 treatments with PV-10 (range 1-4)
Per patient best overall response: 42% complete response, 44% partial response, and 7% stable disease
22% durable response rate (an objective response lasting more than 6 months from the time of first PV-10 treatment)
Median overall survival of 25 months from the first PV-10 treatment; 12-, 24-, 36-, and 48-month overall survival rates of 90%, 85%, 68% and 65%, respectively, from the time of first PV-10 treatment
At least one Grade 1 or 2 treatment-associated adverse event per patient; a total of three treatment-associated Grade 3 adverse events (treatment site ulceration, cellulitis, and photosensitivity reaction)
Dominic Rodrigues, Chairman of the Company's Board of Directors, said, "These data are consistent with prior analyses of patients treated with PV-10 in monotherapy settings as well as the clinical expectations underlying the design of our ongoing pivotal Phase 3 trial. This and other expanded access work, together with our historical and ongoing melanoma clinical trials, strongly support the continued relevance of PV-10 for the treatment of melanoma."
About PV-10
Provectus' lead investigational cancer drug product, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.
About In-Transit Melanoma
According to the current NCCN Guidelines for Patients®, Melanoma, Version 1.2016 2, Stage III in-transit melanoma is when cancer cells have spread into lymph vessels near the first tumor but not into nearby lymph nodes. Melanoma that has spread to a small area of skin near the first tumor is called satellite metastasis. Non-metastatic recurrence is melanoma that has come back after treatment but has not spread to distant parts of the body. According to the NCCN Guidelines for Melanoma, version 1.2018 3, under Treatment for Stage III In-transit Disease, " the tumor burden, time course of appearance, and duration of in-transit disease is variable. In some patients, in-transit lesions remain confined to a region of the body for many years. This may occur in isolation or in combination with other sites of metastatic disease. A major concern in patients in which in-transit disease occurs in isolation is the high probability of subsequent development of visceral metastasis."
About Our Phase 3 Trial of PV-10 as a Monotherapy for Stage III-VI M1a Melanoma
For patients with locally advanced cutaneous melanoma, Provectus is evaluating IL PV-10 versus chemotherapy (dacarbazine or temozolomide) or oncolytic viral therapy in an international, multi-center, pivotal Phase 3 trial (NCT02288897). In-transit, satellite and locally recurrent melanoma patients (Stage IIIB, IIIC or IV M1a) with at least one injectable lesion who are not candidates for treatment with either a checkpoint inhibitor or targeted therapy (with BRAF or combined BRAF/MEK inhibitors) are eligible. The trial's primary endpoint is progression-free survival (assessed via RECIST 1.1 every 12 weeks up to 18 months); complete response rate and overall survival are key secondary endpoints. More information about this Phase 3 trial is available via ClinicalTrials.gov:
https://www.clinicaltrials.gov/ct2/show/NCT02288897
About Provectus
Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017).
References:
1. The first study of expanded access patients treated with PV-10 for in-transit melanoma was authored by investigators at Peter MacCallum Cancer Centre in Melbourne, Australia: Lippey at al., Intralesional PV-10 for in-transit melanoma - a single-center experience. J Surg Oncol. 2016;114: 380–384. https://onlinelibrary.wiley.com/doi/10.1002/jso.24311. Accessed March 15, 2018.
2. National Comprehensive Cancer Network. Patients, Melanoma (Version 1.2016). https://www.nccn.org/patients/guidelines/mpm/files/assets/common/downloads/files/mpm.pdf. Accessed March 15, 2018.
3. National Comprehensive Cancer Network. Melanoma (Version 1.2018). https://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf (registration required). Accessed March 15, 2018.
The complete press release is available at https://www.provectusbio.com/news/press-releases/provectus-pr-20180419-1 on the Provectus website.
Thanks buddy, Quite here!
No, email me.fitzkarz@yahoo.com
Thanks buddy!
$SLDB Volume2.04m
closed @ 9.57 +0.25( 2.68%)
Open9.45
Day's Low9.01
Day's High9.79
52 Wk Low8.95
52 Wk High33.74
Read more at http://thestockmarketwatch.com/stock/?stock=SLDB#CvmKkdwUwGU8sdw4.99
Solid Biosciences Inc.
(NASDAQ : $SLDB)
9.32-16.99( -64.58%)
SLDB PreMarket: $9.40 +0.08 (0.86%) as of 8:40
AM
Read more at http://thestockmarketwatch.com/stock/?stock=SLDB#g7YRdciJZxCejjBf.99
Put on watch, Solid Biosciences Inc.
(NASDAQ : SLDB)
26.31
-0.13
( -0.49%
)
SLDB PreMarket: $10.75 -15.56 (-59.14%) as of 8:28
AM
Read more at http://thestockmarketwatch.com/stock/?stock=SLDB#YAcqopJ8LBBu6Skw.99